Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$13.48
--
Market closed
$13.48
--
Day’s Range― - ―
52-Week Range$4.88 - $19.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$275.43M
Enterprise Value$251.24M
Total Cash (Recent Filing)$126.35M
Total Debt (Recent Filing)$545.00K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Apr 06, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding21,773,272
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-3.38
Price to Sales (P/S)0.00
P/FCF Ratio-10.15
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.12K
Enterprise Value/Ebitda-4.83
Forecast
1Y Price Target
$33.00Price Target Upside144.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Patient RetentionStrong enrollment in the HERO Phase III program and full transition of 12-week trial completers into the open-label extension indicate robust patient retention and favorable safety and tolerability for the pivotal program.
Financial Position And Valuation OpportunityAardvark’s cash runway into 2027 and a perceived valuation gap versus larger obesity peers support continued development and could make the company attractive to investors seeking upside in weight-management therapeutics.
Product Differentiation And MechanismARD-101’s gut bitter receptor mechanism and ARD-201’s oral combination with a DPP-4 inhibitor present a differentiated, potentially more tolerable alternative to injectable GLP-1 therapies, which could attract patients seeking fewer gastrointestinal side effects.
Bears Say
Competitive LandscapeThe rapid emergence of new oral obesity drugs and novel small molecules increases competitive pressure in the mass-market obesity segment and could limit ARD-201’s market adoption.
Efficacy Execution RiskHigh efficacy expectations set by established GLP-1 therapies create execution risk if ARD-201 fails to match comparable weight-loss results and tolerability as a standalone agent.
Pricing And Margin PressureGovernment-driven price reductions for leading weight-loss medications have compressed gross margins across the category, reducing pricing flexibility and the potential profitability of alternatives to peptide therapies.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $275.43M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 54 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.049.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -8.656%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (144.81% Upside)
$33.00 (144.81% Upside)
Insider Transactions
Bought Shares
Worth $144.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-48.06%
Trailing 12-Months
Asset Growth
59.10%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$33.00
▲(144.81% Upside)
Technical Analysis
Ownership Overview
42.42% Insiders
3.06% Mutual Funds
26.38% Other Institutional Investors
22.79% Public Companies and Individual Investors